1227575-47-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-fluoropyrimidine-2-carboxylate serves as a crucial intermediate in the synthesis of pharmaceuticals. Its unique structure allows for the development of compounds with specific therapeutic properties, making it valuable in the creation of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 5-fluoropyriMidine-2-carboxylate is utilized as an intermediate for the synthesis of various agrochemicals. Its role in creating effective pesticides or herbicides is significant, contributing to agricultural productivity and crop protection.
Used in Anticancer Drug Production:
Methyl 5-fluoropyrimidine-2-carboxylate is a key component in the production of fluorouracil-based anticancer drugs. Its incorporation into these medications aids in the treatment of various types of cancer, highlighting its importance in oncology and cancer research.
Safety Note:
Given the nature of Methyl 5-fluoropyrimidine-2-carboxylate as a chemical intermediate, it is imperative to handle and use Methyl 5-fluoropyriMidine-2-carboxylate with care. Adherence to proper safety protocols and procedures is essential to ensure the safety of individuals involved in its production, use, and disposal.

Upstream product

• 67-56-1 methanol 
• 38275-55-7 5- fluoropyrimidine-2-carbonitrile 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

P2X7 MODULATORS

The present invention is directed to a compound of Formula (I): The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invent